Group 1 - State Street Corporation is set to release its third-quarter earnings results on October 17, with expected earnings of $2.65 per share, an increase from $2.26 per share in the same period last year [1] - The consensus estimate for State Street's quarterly revenue is $3.47 billion, compared to $3.26 billion a year earlier [1] - Following the election of Brian Porter to its board of directors, State Street shares fell by 3.2% to close at $112.95 [2] Group 2 - Goldman Sachs analyst Alexander Blostein maintained a Buy rating and raised the price target from $109 to $130 [4] - BMO Capital analyst Brennan Hawken initiated coverage with an Outperform rating and a price target of $130 [4] - Truist Securities analyst David Smith maintained a Buy rating and increased the price target from $125 to $133 [4] - Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating and raised the price target from $117 to $128 [4] - B of A Securities analyst Ebrahim Poonawala maintained an Underperform rating and raised the price target from $106 to $109 [4]

American Express Company (NYSE:AXP) will release earnings results for the third quarter, before the opening bell on Friday, Oct. 17.Analysts expect the New York-based company to report quarterly earnings at $4.00 per share, up from $3.49 per share in the year-ago period. American Express projects quarterly revenue of $18.05 billion, compared to $16.64 billion a year earlier, according to data from Benzinga Pro.The company has beaten analyst estimates for revenue in three straight quarters and in six of the ...

Core Insights - Marriott International, Inc. has a market capitalization of $72.3 billion and operates a diverse portfolio of hotel brands across various price and service levels [1] - The company is expected to announce its fiscal Q3 2025 results on November 4, with analysts predicting an adjusted EPS of $2.38, a 5.3% increase from the previous year [2] - For fiscal 2025, analysts forecast an adjusted EPS of $10.01, representing a 7.3% rise from fiscal 2024, with further growth anticipated to $11.41 in fiscal 2026 [3] Financial Performance - In Q2 2025, Marriott reported an adjusted EPS of $2.65, slightly exceeding Wall Street estimates, with revenue reaching $6.7 billion, driven by strong performance in the upscale and luxury segments [5] - Room revenue in U.S. and Canada luxury properties grew by 4.1%, which helped offset a 1.5% decline in select-service brands [5] Stock Performance and Analyst Ratings - Over the past 52 weeks, shares of Marriott have risen marginally, underperforming compared to the S&P 500 Index's 14.6% increase and the Consumer Discretionary Select Sector SPDR Fund's 18.2% return [4] - Analysts maintain a cautiously optimistic view on MAR stock, with a consensus "Moderate Buy" rating; the average price target is $286.88, indicating a potential upside of 8.8% from current levels [6]

The Travelers Companies, Inc. (NYSE:TRV) will release earnings results for the third quarter, before the opening bell on Thursday, Oct. 16.Analysts expect the New York-based company to report quarterly earnings at $6.30 per share, up from $5.24 per share in the year-ago period. Travelers projects quarterly revenue of $11.15 billion, compared to $10.7 billion a year earlier, according to data from Benzinga Pro.On July 17, Travelers reported better-than-expected second-quarter financial results.Shares of Trav ...

Group 1 - Johnson & Johnson reported better-than-expected third-quarter earnings with adjusted earnings of $2.80 per share, a 15.7% increase year over year, surpassing the consensus of $2.75 [1] - The company achieved sales of $23.99 billion, reflecting a 6.8% year-over-year growth and exceeding the consensus of $23.74 billion [1] - Operational growth was recorded at 5.4%, with adjusted operational growth at 4.4% [1] Group 2 - Johnson & Johnson affirmed its fiscal year 2025 adjusted earnings guidance of $10.80-$10.90, compared to the consensus of $10.87 [2] - The company raised its sales guidance from $93.2 billion-$93.6 billion to $93.5 billion-$93.9 billion, against the consensus of $93.44 billion [2] - Johnson & Johnson announced plans to separate its Orthopedics business to enhance strategic and operational focus [2] Group 3 - Following the earnings announcement, analysts adjusted their price targets for Johnson & Johnson [3] - B of A Securities raised the price target from $198 to $204 while maintaining a Neutral rating [5] - Morgan Stanley increased its price target from $178 to $190 with an Equal-Weight rating [5] - Raymond James raised its price target from $174 to $209 while maintaining an Outperform rating [5] - Stifel increased its price target from $165 to $190 with a Hold rating [5] - Citigroup raised its price target from $213 to $215 while maintaining a Buy rating [5]

The Charles Schwab Corporation (NYSE:SCHW) will release earnings results for the third quarter, before the opening bell on Thursday, Oct. 16.Analysts expect the Westlake, Texas-based company to report quarterly earnings at $1.25 per share, up from 77 cents per share in the year-ago period. Charles Schwab projects quarterly revenue of $6.02 billion, compared to $4.85 billion a year earlier, according to data from Benzinga Pro.On July 18, the company reported second-quarter adjusted earnings per share of $1.1 ...

Core Insights - ConocoPhillips is one of the largest independent exploration and production companies globally, with a market cap of $110.9 billion and operations in 13 countries [1] Financial Performance - The company is expected to announce its Q3 earnings on November 6, with analysts predicting an adjusted EPS of $1.38, a 22.4% decrease from $1.78 in the same quarter last year [2] - For the full fiscal year 2025, adjusted EPS is projected to be $6.32, down 18.9% from $7.79 in 2024, with further decline expected in 2026 to $6.03 per share, a 4.6% year-over-year drop [2] - In Q2, ConocoPhillips reported a topline growth of 4.3% year-over-year to $14.7 billion, although it missed consensus estimates by 1.3% [5] Stock Performance - Over the past 52 weeks, COP stock has decreased by 19.5%, underperforming the Energy Select Sector SPDR Fund's 6.9% decline and the S&P 500 Index's 13.4% gain [3] - Following the release of mixed Q2 results, the stock experienced a slight dip [4] Analyst Sentiment - Despite recent challenges, analysts maintain a positive outlook on ConocoPhillips, with a consensus "Strong Buy" rating. Among 28 analysts, there are 18 "Strong Buys," five "Moderate Buys," and five "Holds" [6] - The mean price target for COP stock is $116.27, indicating a potential upside of 31.9% from current levels [6]

Core Insights - Xylem Inc. is valued at a market cap of $35.5 billion and specializes in engineered products and solutions for various sectors, with Q3 earnings announcement scheduled for October 28, 2025 [1] Financial Performance - Analysts expect Xylem to report a profit of $1.24 per share for Q3 2025, reflecting an 11.7% increase from $1.11 per share in the same quarter last year [2] - For the current fiscal year ending in December, the expected profit is $4.83 per share, up 13.1% from $4.27 per share in fiscal 2024, with further growth anticipated to $5.33 in fiscal 2026 [3] Recent Stock Performance - Xylem's stock has increased by 6.7% over the past 52 weeks, underperforming compared to the S&P 500 Index's 14.4% return and the Industrial Select Sector SPDR Fund's 9.4% increase [4] - Following stronger-than-expected Q2 results, Xylem's shares surged by 10.7% on July 31, with Q2 revenue rising 6.1% year-over-year to $2.3 billion, exceeding consensus estimates by 4.1% [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for Xylem, with 13 out of 21 analysts recommending "Strong Buy," one suggesting "Moderate Buy," and seven advising "Hold" [6] - The mean price target for Xylem is set at $162.81, indicating an 11.5% potential upside from current levels [6]

Core Viewpoint - Abbott Laboratories is set to release its third-quarter earnings results on October 15, with expectations of increased earnings and revenue compared to the previous year [1]. Financial Performance - Analysts predict Abbott will report earnings of $1.30 per share, an increase from $1.21 per share in the same quarter last year [1]. - The company is projected to generate quarterly revenue of $11.4 billion, up from $10.63 billion a year earlier [1]. Dividend Information - On September 19, Abbott's board declared a quarterly common dividend of 59 cents per share [2]. Stock Performance - Abbott Laboratories shares experienced a decline of 0.6%, closing at $132.57 [2]. Analyst Ratings - Citigroup analyst Joanne Wuensch maintained a Buy rating but reduced the price target from $157 to $155 [4]. - Raymond James analyst Jayson Bedford kept an Outperform rating while lowering the price target from $142 to $141 [4]. - Mizuho analyst Anthony Petrone maintained a Neutral rating and cut the price target from $140 to $135 [4]. - Jefferies analyst Matthew Taylor upgraded the stock from Hold to Buy and raised the price target from $143 to $145 [4]. - BTIG analyst Marie Thibault maintained a Buy rating but reduced the price target from $148 to $145 [4].

Core Insights - CoStar Group, Inc. (CSGP) has a market capitalization of $32 billion and is a leading provider of information, analytics, and online marketplace services for the global commercial real estate industry [1] - The company is expected to report a fiscal Q3 2025 EPS of $0.10, reflecting a 44.4% decrease from $0.18 in the same quarter last year, although it has a history of exceeding Wall Street estimates [2] - For fiscal 2025, analysts forecast an EPS of $0.51, down 5.6% from $0.54 in fiscal 2024, but anticipate a significant increase to $1.18 in fiscal 2026, representing a 131.4% year-over-year surge [3] Stock Performance - CSGP stock has increased by 1% over the past 52 weeks, underperforming the S&P 500 Index, which rose by 13.4%, but outperformed the Real Estate Select Sector SPDR Fund, which decreased by 5.4% [4] - Following the release of Q2 2025 results, CSGP shares rose by 6.9% after reporting an adjusted EPS of $0.17 and revenue of $781.3 million, driven by a 65% increase in net new bookings [5] Analyst Ratings - The consensus rating for CSGP stock is "Moderate Buy," with 17 analysts covering the stock: nine recommend "Strong Buy," two suggest "Moderate Buy," five advise "Hold," and one rates it as "Strong Sell" [6] - The average analyst price target for CoStar Group is $97, indicating a potential upside of 28.3% from current levels [6]